On February 4, the state drug administration issued a notice formally, entrusted by jilin province west pharmaceutical technology development co., LTD., are biological finish BE research (strategic business unit of changsha central hospital clinical) of escitalopram oxalate citalopram tablets "formally approved, the company successfully approved the second" escitalopram oxalate citalopram tablets "project.

Escitalopram oxalate is an antidepressant indicated for the treatment of depressive disorders, panic disorder with or without agoraphobia. On May 22, 2018, the first "escitalopram oxalate tablet" project completed by Duzheng Biological was approved for production, entrusted by Dongting Pharmaceutical. This variety is also the first approved generic drug conformity evaluation variety in Hunan Province, which is of great significance.